Rubin Eyal 4/A
4/A · Protalix BioTherapeutics, Inc. · Filed Aug 14, 2020
Insider Transaction Report
Form 4/AAmended
Rubin Eyal
Sr. VP & CFO
Transactions
- Award
Common Stock
2020-08-11+246,146→ 246,146 total(indirect: By Trust)
Footnotes (3)
- [F1]The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares.
- [F2]Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.
- [F3]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.